Long-Term Survival in Bilateral Lung Transplantation for Scleroderma-Related Lung Disease

Chan, Edward Y.; Goodarzi, Ahmad; Sinha, Neeraj; Nguyen, Duc T.; Youssef, J.G.; Suarez, Erik E.; Kaleekal, Thomas; Graviss, Edward A.; Bruckner, Brian A.; MacGillivray, Thomas E.; Scheinin, S.

doi:10.1016/j.athoracsur.2017.09.038

Cited by 26 publications

(21 citation statements)

References 19 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…144 Similar survival rates have been reported in several prior studies. [145][146][147][148][149][150] Esophageal involvement in SSc is usually the most significant concern with regard to transplantation. Links between gastroesophageal reflux, which is common posttransplant even in the absence of SSc, and chronic lung allograft dysfunction are widely accepted.…”

Section: Lung Transplantation In Ssc-ildmentioning

confidence: 99%

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Mackintosh

Stainer

Barnett

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc). SSc-ILD adversely impacts quality of life and is currently the leading cause of death in this multisystem disease. Identifying clinically significant SSc-ILD is critically important. Accurate staging and prognostication remain difficult; however, significant advances have been made in the last decade. Evidence supports the need to treat patients with extensive and/or progressive SSc-ILD, while only a subset of patients with limited ILD may require treatment. Research is urgently required to allow improved prediction of patients at risk of ILD progression at an early point in the disease, and ideally prior to its onset, to allow prevention. The last decade has seen the publication of landmark clinical trials for SSc-ILD. More effective strategies with less toxicity are under investigation. For those with refractory or very advanced disease, studies into disease-specific palliative approaches are in their infancy. Lung transplantation as an option for SSc-ILD remains patient- and center-specific, with data to suggest equivalent outcomes to other fibrotic lung diseases, in carefully selected cases. This review aims to provide a comprehensive overview of all key aspects of SSc-ILD.

show abstract

Section: Lung Transplantation In Ssc-ildmentioning

confidence: 99%

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Mackintosh

Stainer

Barnett

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…For patients with end-stage lung disease (estimated 2 year survival <50%), lung transplantation should be considered (54). It is encouraging that long-term outcomes in SSc-ILD post-lung transplanation appear similar to those in other forms of lung disease not associated with scleroderma (55).…”

Section: Background On Ildmentioning

confidence: 99%

Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma

Simms

2020

Arthritis & Rheumatology

View full text Add to dashboard Cite

You are consulted to evaluate a 56‐year‐old woman with known Raynaud's phenomenon, finger swelling of several; months’ duration, and new hypertension with a blood pressure of 160/100 mm/Hg. She also reports progressive shortness of breath. Physical examination reveals telangiectasias, sclerodactyly, and proximal skin sclerosis (thick shiny skin on the chest and upper arms), and bibasilar crackles are found on chest examination. Laboratory tests reveal evidence of microangiopathic hemolytic anemia, thrombocytopenia, and elevation of the serum creatinine level (previously normal), and chest computed tomography shows evidence of ground‐glass opacification in both lower lung fields.

show abstract

“…Reviews specific to LTx in various disease states included idiopathic pulmonary fibrosis, [51][52][53] scleroderma, [54][55][56][57][58] emphysema, 59,60 chronic obstructive pulmonary disease (COPD), 61 pulmonary veno-occlusive disease, 62 CF, 63,64 pulmonary hypertension, [65][66][67] and occupational lung disease. 68 Cystic Fibrosis.…”

Section: Recipient Managementmentioning

confidence: 99%

Noteworthy Literature Published in 2018 for Thoracic Organ Transplantation

Tawil

Adams

Nicoara

et al. 2019

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

Publications of note from 2018 are reviewed for the cardiothoracic transplant anesthesiologist. Strategies to expand the availability of donor organs were highlighted, including improved donor management, accumulating experience with increased-risk donors, ex vivo perfusion techniques, and donation after cardiac death. A number of reports examined posttransplant outcomes, including outcomes other than mortality, with new data-driven risk models. Use of extracorporeal support in cardiothoracic transplantation was a prominent theme. Major changes in adult heart allocation criteria were implemented, aiming to improve objectivity and transparency in the listing process. Frailty and prehabilitation emerged as targets of comprehensive perioperative risk mitigation programs.

show abstract

Long-Term Survival in Bilateral Lung Transplantation for Scleroderma-Related Lung Disease

Cited by 26 publications

References 19 publications

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview

Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma

Noteworthy Literature Published in 2018 for Thoracic Organ Transplantation

Contact Info

Product

Resources

About